Moscow (Russia): Sputnik V demonstrates high virus-neutralising activity against Covid-19 Omicron variant, according to a study by Gamaleya Centre's preliminary laboratory.
Gamaleya Centre's preliminary laboratory study shows that Sputnik V demonstrates high virus-neutralising activity (VNA) against the #Omicron (B.1.1.529) variant and is expected to provide a strong defense against severe disease and hospitalisation, according to Sputnik V press release.
Earlier, the study was conducted using sera with a long period after vaccination (more than 6 months after vaccination) as an indicator of Sputnik V's long-lasting protection, Sputnik V's statement mentioned.
Further, the preliminary study by the Gamaleya Centre has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster (based on human adenovirus serotype 26, the first component of Sputnik V) are effective against Omicron (B.1.1.529) variant of COVID, providing for better protection when compared to other vaccines.
Also, Heterologous boosting with Sputnik Light is the solution to increase other vaccines' efficacy, including against Omicron, and extend the booster protection period.
Also, Sputnik Light as a booster significantly increases virus neutralising activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response, according to Sputnik V's press release.
Earlier, Sputnik Light has already been registered in more than 25 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, Philippines, and San Marino).
Sputnik V has been authorised in 71 countries with total population of over 4 billion people.
Further, Sputnik Light has already shown strong results used as a booster in mix and match trials in Argentina.